|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
F-star Therapeutics, Inc (FSTX) |
|
|
$7.12 0.00 (0.00%) as of 4:30 Tue 3/7
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,620,000 |
| Market
Cap: |
146.81(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.12 - $7.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile F-star Therapeutics is a clinical-stage biopharmaceutical company. Co. is engaged in the discovery and development of therapeutics for the treatment of a range of cancers and inflammatory diseases. Co.'s STING (STimulator of INterferon Genes) product portfolio include STING agonist clinical program in oncology, STING antagonist compounds for inflammatory diseases, and STING agonist antibody drug conjugate program for oncology. Co. is developing its SB 11285, as an immunotherapeutic cyclic dinucleotide for the treatment of selected cancers. Co. is also exploring the use of its STING antagonist compounds for the treatment of certain autoimmune and inflammatory diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arkowitz David |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$59,708 |
D/D |
(8,386) |
0 |
|
- |
|
| Bermingham Nessan |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$45,055 |
D/D |
(6,328) |
0 |
|
- |
|
| Bermingham Nessan |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$694,535 |
D/D |
(97,547) |
6,328 |
|
- |
|
| Brewis Neil |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$66,750 |
D/D |
(9,375) |
0 |
|
- |
|
| Brewis Neil |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$748,227 |
D/D |
(105,088) |
9,375 |
|
- |
|
| Deptula-Hicks Darlene M |
See Remarks |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$181,838 |
D/D |
(25,539) |
0 |
|
- |
|
| Deptula-Hicks Darlene M |
See Remarks |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$219,994 |
D/D |
(30,898) |
25,539 |
|
- |
|
| Forster Eliot |
PRESIDENT AND CEO |
• • – |
2023-03-08 |
4 |
D |
$7.12 |
$526,588 |
D/D |
(73,959) |
0 |
|
- |
|
| Forster Eliot |
PRESIDENT AND CEO |
• • – |
2023-03-08 |
4 |
D |
$7.12 |
$2,474,755 |
D/D |
(347,578) |
73,959 |
|
- |
|
| Race Geoffrey |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$28,031 |
D/D |
(3,937) |
0 |
|
- |
|
| Brady Todd C |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$106,828 |
D/D |
(15,004) |
0 |
|
- |
|
| Benz Edward Jr |
Director |
– • – |
2023-03-08 |
4 |
D |
$7.12 |
$31,221 |
D/D |
(4,385) |
0 |
|
- |
|
| Kayitalire Louis |
CHIEF MEDICAL OFFICER |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$178,135 |
D/D |
(25,019) |
0 |
|
- |
|
| Kayitalire Louis |
CHIEF MEDICAL OFFICER |
• – – |
2023-03-08 |
4 |
D |
$7.12 |
$208,160 |
D/D |
(29,236) |
25,019 |
|
- |
|
| Race Geoffrey |
Director |
– • – |
2022-07-29 |
4 |
OE |
$0.11 |
$433 |
D/D |
3,937 |
3,937 |
|
- |
|
| Brewis Neil |
Chief Scientific Officer |
• – – |
2022-07-29 |
4 |
OE |
$0.11 |
$8,428 |
D/D |
76,619 |
114,463 |
|
- |
|
| Forster Eliot |
President and CEO |
• • – |
2022-07-29 |
4 |
OE |
$0.11 |
$28,707 |
D/D |
260,977 |
421,537 |
|
- |
|
| Kayitalire Louis |
Chief Medical Officer |
• – – |
2021-11-02 |
4 |
AS |
$6.81 |
$437 |
D/D |
(64) |
54,255 |
|
-58% |
|
| Kayitalire Louis |
Chief Medical Officer |
• – – |
2021-10-04 |
4 |
AS |
$7.23 |
$462 |
D/D |
(64) |
54,319 |
|
-53% |
|
| Kayitalire Louis |
Chief Medical Officer |
• – – |
2021-07-02 |
4 |
AS |
$8.43 |
$8,885 |
D/D |
(1,054) |
54,383 |
|
-19% |
|
| Forster Eliot |
President and CEO |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
142,000 |
160,560 |
|
- |
|
| Benz Edward Jr |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,385 |
4,385 |
|
- |
|
| Bermingham Nessan |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
103,875 |
|
- |
|
| Kayitalire Louis |
Chief Medical Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
55,437 |
|
- |
|
| Brewis Neil |
Chief Scientific Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
37,844 |
|
- |
|
134 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
